LISA SATTER to STAT1 Transcription Factor
This is a "connection" page, showing publications LISA SATTER has written about STAT1 Transcription Factor.
Connection Strength
1.273
-
STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition. N Engl J Med. 2020 10 08; 383(15):1494-1496.
Score: 0.341
-
Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency. J Clin Immunol. 2018 10; 38(7):753-756.
Score: 0.297
-
Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017 May; 139(5):1629-1640.e2.
Score: 0.264
-
Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 11; 142(5):1665-1669.
Score: 0.146
-
Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018 06; 141(6):2142-2155.e5.
Score: 0.139
-
More on STAT1 Gain of Function, Type 1 Diabetes, and JAK Inhibition. Reply. N Engl J Med. 2021 01 07; 384(1):93-94.
Score: 0.087